Fujifilm makes huge investments in healthcare but will not ditch camera industry entirely

Fujifilm is unable to generate revenues from its imaging portfolio. Post coronavirus crunch, the company is investing heavily in pharmaceuticals rather than its camera business.

Fujifilm is one of the biggest camera makers in the industry, yet the Covid-19 pandemic didn't allow it to make tracks. The company has two dedicated lines of cameras -one, digital cameras, and two, its instant photo system called instax. Even then, Fujifilm is unable to generate revenues from its imaging portfolio. Post coronavirus crunch, the company is investing heavily in pharmaceuticals rather than its camera business. In a report coming in from Reuters, it is noted that Fujifilm is focusing on its drug ingredients business to drive future profits. Fujifilm Toyama Chemical Co. Ltd. announced a phase III clinical trial for its anti-influenza drug Avigan tablet, in Japan, a couple of months ago. The tablet targets patients infected with novel coronavirus infections.